- Home
- RRR vs EWTX Comparison
RRR vs EWTX Comparison
Compare RRR & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRR | EWTX |
|---|---|---|
| Founded | 1976 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RRR | EWTX |
|---|---|---|
| Price | $65.61 | $39.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $69.69 | $39.00 |
| AVG Volume (30 Days) | 579.9K | ★ 979.1K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | ★ 23.32 | N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $2,011,483,000.00 | N/A |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $4.62 | N/A |
| P/E Ratio | $90.45 | ★ N/A |
| Revenue Growth | ★ 3.74 | N/A |
| 52 Week Low | $50.52 | $12.31 |
| 52 Week High | $68.99 | $48.40 |
Technical Indicators
Market Signals| Indicator | RRR | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.43 | 50.40 |
| Support Level | $59.81 | $37.81 |
| Resistance Level | $68.17 | $40.36 |
| Average True Range (ATR) | 1.62 | 2.34 |
| MACD | -0.18 | -0.30 |
| Stochastic Oscillator | 56.34 | 24.90 |
Price Performance
Historical ComparisonAbout RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos, followed by Food and Beverages, Rooms and others.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.